睿知中国医院研究地图
候选清单

即将招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer

ClinicalTrials.gov 上登记的一项肺癌开放试验,由Anhui Provincial Cancer Hospital牵头,本站收录的另外 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 2

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方Anhui Provincial Cancer Hospital城市未列出医院页面
  2. 研究中心安徽省肿瘤医院Anhui Provincial Cancer Hospital合肥医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07661173,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Have histologically or cytologically confirmed non-squamous non-small cell lung cancer.

    入选标准第 3 条

    Confirmed presence of EGFR-sensitive mutation-positive by tumor histology, cytology, hematology, or pleural effusion supernatant;

    入选标准第 4 条

    Confirmed presence of EGFR mutation-positive by tumor histology, cytology, or hematology;

    入选标准第 9 条

  3. unstable angina, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) classification of ≥ 2;

    排除标准第 21 条

  4. According to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1), there must be at least one measurable lesion on imaging. Lesions located within the previous radiation field that have proven progression can be considered measurable;

    入选标准第 6 条

    If there is a risk of pregnancy, all subjects (regardless of gender) must use contraception with an annual failure rate of less than 1% throughout the treatment period until 120 days after the last dose of study drug (or 180 days after the last dose of study drug).

    入选标准第 23 条

    received systemic anti-tumor therapy within 3 weeks before treatment, such as chemotherapy, targeted therapy, immunotherapy (including Chinese herbal medicine therapy with anti-tumor indications), etc.;

    排除标准第 3 条

    received any investigational drug therapy within 4 weeks before treatment;

    排除标准第 4 条

    received high-dose immunosuppressive drugs (systemic glucocorticoids exceeding 10mg/day of prednisone or its equivalent dose) within 4 weeks before treatment;

    排除标准第 5 条

    Subjects who have received chest radiotherapy exceeding 30 Gy within 6 months prior to treatment or palliative radiotherapy of 30 Gy or less within 7 days prior to treatment (palliative radiotherapy for bone or intracranial lesions is allowed);

    排除标准第 10 条

    Subjects who have experienced active autoimmune diseases requiring systemic treatment (such as the use of disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Alternative therapies (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic treatment;

    排除标准第 11 条

    Subjects who have not fully recovered from toxicity and/or complications caused by any intervention prior to the start of treatment (i.e., grade ≤1 or baseline, excluding fatigue or alopecia);

    排除标准第 13 条

  5. ECOG score of 0-1;

    入选标准第 5 条

  6. Absolute neutrophil count (ANC) ≥1.5x10\^9/L without the use of granulocyte colony-stimulating factor in the past 14 days;

    入选标准第 13 条

    Platelets ≥100×10\^9/L without blood transfusion in the past 14 days;

    入选标准第 14 条

    Hemoglobin >9g/dL without blood transfusion or erythropoietin use in the past 14 days;

    入选标准第 15 条

    Total bilirubin ≤1.5×upper limit of normal (ULN);

    入选标准第 16 条

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN (subjects with liver metastasis are allowed to have ALT or AST ≤5×ULN);

    入选标准第 17 条

    Serum creatinine ≤1.5×ULN and creatinine clearance rate (calculated using the Cockcroft-Gault formula) ≥60 ml/min;

    入选标准第 18 条

  7. The pathology is small cell lung cancer (SCLC), including lung cancer with a mixture of SCLC and non-small cell lung cancer (NSCLC);

    排除标准第 1 条

    Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1/2 antibody positive);

    排除标准第 14 条

    Subjects with active HCV infection (HCV antibody positive and HCV-RNA level above the detection limit);

    排除标准第 16 条

  8. For female subjects of childbearing age, urine or serum pregnancy tests must be conducted within 3 days before the first dose of study drug (on Day 1 of Cycle 1) and the results must be negative. If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Non-childbearing age females are defined as those who have been postmenopausal for at least 1 year, or have undergone surgical sterilization or hysterectomy;

    入选标准第 22 条

    Pregnant or lactating women;

    排除标准第 18 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07661173,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Sign a written informed consent before implementing any trial-related procedures;
  2. At least 18 years of age;
  3. Have histologically or cytologically confirmed non-squamous non-small cell lung cancer.
  4. Confirmed presence of EGFR-sensitive mutation-positive by tumor histology, cytology, hematology, or pleural effusion supernatant;
  5. ECOG score of 0-1;
  6. According to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1), there must be at least one measurable lesion on imaging. Lesions located within the previous radiation field that have proven progression can be considered measurable;
  7. Life expectancy >3 months at Day 1;
  8. Patients newly diagnosed with locally advanced (IIIB-IIIC), metastatic, or recurrent (stage IV) lung cancer according to the 9th edition of the TNM classification by the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer; not suitable for treatment with surgery or radiotherapy;
  9. Confirmed presence of EGFR mutation-positive by tumor histology, cytology, or hematology;
  10. Not previously treated with anti-angiogenic drugs/chemotherapy;
  11. Brain metastasis patients are allowed to be enrolled, as long as they meet the following conditions:
  12. Sufficient organ function, and the subjects must meet the following laboratory criteria:
  13. Absolute neutrophil count (ANC) ≥1.5x10\^9/L without the use of granulocyte colony-stimulating factor in the past 14 days;
  14. Platelets ≥100×10\^9/L without blood transfusion in the past 14 days;
  15. Hemoglobin >9g/dL without blood transfusion or erythropoietin use in the past 14 days;
  16. Total bilirubin ≤1.5×upper limit of normal (ULN);
  17. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN (subjects with liver metastasis are allowed to have ALT or AST ≤5×ULN);
  18. Serum creatinine ≤1.5×ULN and creatinine clearance rate (calculated using the Cockcroft-Gault formula) ≥60 ml/min;
  19. Good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN;
  20. Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within the normal range. If the baseline TSH exceeds the normal range, subjects with total T3 (or FT3) and FT4 within the normal range may also be enrolled;
  21. myocardial enzyme profile within the normal range (subjects with simple laboratory abnormalities that the investigator comprehensively judges to have no clinical significance are also allowed to be enrolled);
  22. For female subjects of childbearing age, urine or serum pregnancy tests must be conducted within 3 days before the first dose of study drug (on Day 1 of Cycle 1) and the results must be negative. If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Non-childbearing age females are defined as those who have been postmenopausal for at least 1 year, or have undergone surgical sterilization or hysterectomy;
  23. If there is a risk of pregnancy, all subjects (regardless of gender) must use contraception with an annual failure rate of less than 1% throughout the treatment period until 120 days after the last dose of study drug (or 180 days after the last dose of study drug).

排除标准:Exclusion Criteria:

  1. The pathology is small cell lung cancer (SCLC), including lung cancer with a mixture of SCLC and non-small cell lung cancer (NSCLC);
  2. The patient has received the following treatments:
  3. received systemic anti-tumor therapy within 3 weeks before treatment, such as chemotherapy, targeted therapy, immunotherapy (including Chinese herbal medicine therapy with anti-tumor indications), etc.;
  4. received any investigational drug therapy within 4 weeks before treatment;
  5. received high-dose immunosuppressive drugs (systemic glucocorticoids exceeding 10mg/day of prednisone or its equivalent dose) within 4 weeks before treatment;
  6. received attenuated live vaccines within 4 weeks before treatment (or plans to receive attenuated live vaccines during the study period);
  7. underwent major surgery (such as thoracotomy, thoracotomy, or Kaifu surgery) within 4 weeks before treatment, or has unhealed surgical wounds, ulcers, or fractures.
  8. Subjects with clinically uncontrollable pleural/peritoneal effusion (not requiring drainage of effusion or showing no significant increase in effusion after 3 days of cessation of drainage) may be enrolled;
  9. Subjects with a history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonia requiring steroid treatment, or any evidence of clinically active ILD;
  10. Subjects who have received chest radiotherapy exceeding 30 Gy within 6 months prior to treatment or palliative radiotherapy of 30 Gy or less within 7 days prior to treatment (palliative radiotherapy for bone or intracranial lesions is allowed);
  11. Subjects who have experienced active autoimmune diseases requiring systemic treatment (such as the use of disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Alternative therapies (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic treatment;
  12. Known allogeneic organ transplantation (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplantation;
  13. Subjects who have not fully recovered from toxicity and/or complications caused by any intervention prior to the start of treatment (i.e., grade ≤1 or baseline, excluding fatigue or alopecia);
  14. Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1/2 antibody positive);
  15. Untreated active hepatitis B (defined as HBsAg positive with HBV-DNA copy number greater than the upper limit of normal in the laboratory department of the research center); Note: Subjects with hepatitis B who meet the following criteria may also be enrolled: 1) HBV viral load <1000 copies/ml (200 IU/ml) prior to the first dose, and subjects should receive anti-HBV treatment throughout the study drug treatment period to avoid viral reactivation; 2) For subjects with anti-HBc (+), HBsAg (-), anti-HBs (-), and HBV viral load (-), prophylactic anti-HBV treatment is not required, but close monitoring for viral reactivation is necessary.
  16. Subjects with active HCV infection (HCV antibody positive and HCV-RNA level above the detection limit);
  17. Subjects who have received a live vaccine within 30 days prior to the first dose (Cycle 1, Day 1); Note: Inactivated virus vaccine for seasonal influenza administered via injection is allowed within 30 days prior to the first dose; however, attenuated live influenza vaccine administered intranasally is not allowed.
  18. Pregnant or lactating women;
  19. Subjects with any severe or uncontrollable systemic diseases, such as:
  20. significant and symptomatically severe abnormalities in rhythm, conduction, or morphology on resting electrocardiogram, such as complete left bundle branch block, second-degree or higher heart block, ventricular arrhythmias, or atrial fibrillation;
  21. unstable angina, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) classification of ≥ 2;
  22. myocardial infarction within 6 months prior to enrollment;
  23. poorly controlled blood pressure (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg);
  24. history of non-infectious pneumonia requiring glucocorticoid treatment within 1 year prior to the first dose, or current clinically active interstitial lung disease;
  25. active tuberculosis;
  26. active or uncontrollable infections requiring systemic treatment;
  27. clinically active diverticulitis, abdominal abscess, or gastrointestinal obstruction;
  28. liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;
  29. poorly controlled diabetes (fasting blood glucose (FBG) >10 mmol/L);
  30. urine routine test indicating proteinuria ≥++ and confirmed 24-hour urine protein quantitation >1.0 g;
  31. subjects with mental disorders and unable to cooperate with treatment; subjects with medical history or disease evidence, treatment, or laboratory test values that may interfere with trial results, hinder the subject's full participation in the study, or other situations deemed unsuitable for enrollment by the investigator; subjects deemed by the investigator to have other potential risks and are not suitable to participate in this study

引自 ClinicalTrials.gov, NCT07661173, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07661173,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07661173